Team:Queens Canada/Safety/FAQs
From 2011.igem.org
Line 8: | Line 8: | ||
- | <body onload="runAccordion(5, | + | <body onload="runAccordion(5,150)"> |
<SCRIPT LANGUAGE="javascript" TYPE="text/javascript"><!-- | <SCRIPT LANGUAGE="javascript" TYPE="text/javascript"><!-- | ||
Line 58: | Line 58: | ||
<div id="rightcontenttext"> <p><p> | <div id="rightcontenttext"> <p><p> | ||
- | < | + | <h3red>Frequently Asked Questions </h3red> <p> |
<regulartext4><b> | <regulartext4><b> | ||
Would the materials used in your project and/or your final product pose: </b> </regulartext4><br> | Would the materials used in your project and/or your final product pose: </b> </regulartext4><br> | ||
- | <span class=" | + | <span class="classredt2"><a href="#1a" onclick="return bottom(450)">a. Risks to the safety and health of team members or others in the lab?</a><span><br> |
- | <span class=" | + | <span class="classredt2"><a href="https://2011.igem.org/Team:Queens_Canada/Safety/FAQs#1b">b. Risks to the safety and health of the general public if released by |
design or accident?</a><span><br> | design or accident?</a><span><br> | ||
- | <span class=" | + | <span class="classredt2"><a href="https://2011.igem.org/Team:Queens_Canada/Safety/FAQs#1c">c. Risks to environmental quality if released by design or accident?</a><span><br> |
- | <span class=" | + | <span class="classredt2"><a href="https://2011.igem.org/Team:Queens_Canada/Safety/FAQs#1d">d. Risks to security through malicious misuse by individuals, groups or states?</a><span><p> |
<regulartext4> <b> | <regulartext4> <b> | ||
Specifically, are any parts or devices in your project associated with: </b> </regulartext4><br> | Specifically, are any parts or devices in your project associated with: </b> </regulartext4><br> | ||
- | <span class=" | + | <span class="classredt2"><a href="https://2011.igem.org/Team:Queens_Canada/Safety/FAQs#2a">a. Pathogenicity, infectivity, or toxicity? </a><span><br> |
- | <span class=" | + | <span class="classredt2"><a href="https://2011.igem.org/Team:Queens_Canada/Safety/FAQs#2b">b. Threats to environmental quality?</a><span><br> |
- | <span class=" | + | <span class="classredt2"><a href="https://2011.igem.org/Team:Queens_Canada/Safety/FAQs#2c">c. Security concerns?</a><span><p> |
Line 107: | Line 107: | ||
<div id="rightcontenttext"> <p><p> | <div id="rightcontenttext"> <p><p> | ||
<a name="1a"> </a> | <a name="1a"> </a> | ||
- | < | + | <h3red1> Would the materials used in your project and/or your final product pose:</h3red1> <p> |
- | < | + | <h3red1><b>a. Risks to the safety and health of team members or others in the lab?</b></h3red1> <br> |
<regulartext> | <regulartext> | ||
The potential carcinogen ethidium bromide was used in our gel electrophoresis experiments. We followed our labs standard protocols for dealing with the substance, which includes the use of protective material and steps to minimize the use of ethidium bromide. As well, the carcinogen naphthalene was used in our chemotaxis assays. Care was taken to handle all chemicals in a well-ventilated area, using appropriate safety attire. | The potential carcinogen ethidium bromide was used in our gel electrophoresis experiments. We followed our labs standard protocols for dealing with the substance, which includes the use of protective material and steps to minimize the use of ethidium bromide. As well, the carcinogen naphthalene was used in our chemotaxis assays. Care was taken to handle all chemicals in a well-ventilated area, using appropriate safety attire. | ||
Line 116: | Line 116: | ||
<a name="1b"> </a> | <a name="1b"> </a> | ||
- | < | + | <h3red1><b>b. Risks to the safety and health of the general public if released by design or accident?</b></h3red1> <br> |
<regulartext> | <regulartext> | ||
In any transgenic organism, a potential risk could be posed to human and ecosystem health due to their novel genetics conferring an evolutionary advantage over wild type organisms. Given this, this project is designed to minimize the possibility that such an event could occur. Caenorhabditis elegans is not known to be pathogenic in humans. Furthermore, the extrachromosomal assay used in the microinjection process greatly weakens the constitution of transgenetic C.elegans. | In any transgenic organism, a potential risk could be posed to human and ecosystem health due to their novel genetics conferring an evolutionary advantage over wild type organisms. Given this, this project is designed to minimize the possibility that such an event could occur. Caenorhabditis elegans is not known to be pathogenic in humans. Furthermore, the extrachromosomal assay used in the microinjection process greatly weakens the constitution of transgenetic C.elegans. |
Revision as of 04:59, 28 September 2011
a. Risks to the safety and health of team members or others in the lab?
b. Risks to the safety and health of the general public if released by
design or accident?
c. Risks to environmental quality if released by design or accident?
d. Risks to security through malicious misuse by individuals, groups or states?
a. Pathogenicity, infectivity, or toxicity?
b. Threats to environmental quality?
c. Security concerns?
a. Does your institution have its own bio-safety rules and if so what are they?
b. Does your institution have an Institutional Biosafety Committee or
equivalent group? If yes, have you discussed your project with them?
c. Will / did you receive any biosafety and/or lab training before
beginning your project? If so, describe this training.
d. Does your country have national biosafety regulations or
guidelines?
a. How could parts, devices and systems be made even safer through biosafety engineering?